


FIG.1A

SEP 09 2002
PATENT & TRADEMARK OFFICE

POSTOPERATIVE DAY: 5




NECROTIC	HEALTHY AREA
HEMORRHAGIC AREA	LESS HEALTHY AREA
	ANIMAL DIED

FIG.1B



POSTOPERATIVE DAY: 7



NECROTIC

HEALTHY AREA

HEMORRHAGIC
AREA


LESS
HEALTHY AREA

ANIMAL DIED

FIG.1C



POSTOPERATIVE DAY: 8



NECROTIC



HEALTHY AREA



HEMORRHAGIC
AREA




LESS
HEALTHY AREA



ANIMAL DIED

FIG.1D



NECROTIC

HEALTHY AREA

HEMORRHAGIC AREA


LESS HEALTHY AREA

ANIMAL DIED

FIG.1E



POSTOPERATIVE DAY: 10



NECROTIC

HEALTHY AREA

HEMORRHAGIC
AREA

LESS
HEALTHY AREA

ANIMAL DIED

FIG.1F

SEP 09 2002

Inventor(s): SRIVASTAVA AND CHANDAWARKAR

Title: "METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTION USING HEAT SHOCK PROTEINS"

DAY 8

MOUSE

#1

MOUSE

#2

NO TREATMENT



BUFFER
INTRODUCED
INTRATERMINALLY



BUFFER
INTRODUCED
SUBCUTANEOUSLY



1 μ g gp96
ADMINISTERED
INTRATERMINALLY



10 μ g gp96
ADMINISTERED
INTRATERMINALLY



10 μ g gp96
ADMINISTERED
SUBCUTANEOUSLY



100 μ g gp96
ADMINISTERED
INTRATERMINALLY



100 μ g gp96
ADMINISTERED
SUBCUTANEOUSLY



200 μ g gp96
ADMINISTERED
SUBCUTANEOUSLY



10 μ g OF RAT gp96
ADMINISTERED
INTRATERMINALLY



NECROTIC

HEMORRHAGIC
AREA

GRAFT FALLEN
OFF; UNDERLYING
WOUND VISABLE

HEALTHY AREA

LESS
HEALTHY AREA

ANIMAL DIED

FIG.2A




FIG.2B

DAY 14



























	MOUSE #1	MOUSE #2	
NO TREATMENT			
BUFFER INTRODUCED INTRATERMINALLY			
BUFFER INTRODUCED SUBCUTANEOUSLY			
1 μ g gp96 ADMINISTERED INTRATERMINALLY			
10 μ g gp96 ADMINISTERED INTRATERMINALLY			 NECROTIC
10 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 HEMORRHAGIC AREA
100 μ g gp96 ADMINISTERED INTRATERMINALLY			 GRAFT FALLEN OFF; UNDERLYING WOUND VISABLE
100 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 HEALTHY AREA
200 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 LESS HEALTHY AREA
10 μ g OF RAT gp96 ADMINISTERED INTRATERMINALLY			 ANIMAL DIED

FIG.2C

DAY 16



























	MOUSE #1	MOUSE #2	
NO TREATMENT			
BUFFER INTRODUCED INTRATERMINALLY			
BUFFER INTRODUCED SUBCUTANEOUSLY			
1 μ g gp96 ADMINISTERED INTRATERMINALLY			
10 μ g gp96 ADMINISTERED INTRATERMINALLY			 NECROTIC
10 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 HEMORRHAGIC AREA
100 μ g gp96 ADMINISTERED INTRATERMINALLY			 GRAFT FALLEN OFF; UNDERLYING WOUND VISABLE
100 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 HEALTHY AREA
200 μ g gp96 ADMINISTERED SUBCUTANEOUSLY			 LESS HEALTHY AREA
10 μ g OF RAT gp96 ADMINISTERED INTRATERMINALLY			 ANIMAL DIED

FIG.2D



DAY 19		
	MOUSE #1	MOUSE #2
NO TREATMENT		
BUFFER INTRODUCED INTRATERMINALLY		
BUFFER INTRODUCED SUBCUTANEOUSLY		
1 μ g gp96 ADMINISTERED INTRATERMINALLY		
10 μ g gp96 ADMINISTERED INTRATERMINALLY		
10 μ g gp96 ADMINISTERED SUBCUTANEOUSLY		
100 μ g gp96 ADMINISTERED INTRATERMINALLY		
100 μ g gp96 ADMINISTERED SUBCUTANEOUSLY		
200 μ g gp96 ADMINISTERED SUBCUTANEOUSLY		
10 μ g OF RAT gp96 ADMINISTERED INTRATERMINALLY		

NECROTIC

HEMORRHAGIC AREA

GRAFT FALLEN OFF; UNDERLYING WOUND VISABLE

HEALTHY AREA

LESS HEALTHY AREA

ANIMAL DIED

FIG.2E




FIG.3A

SEP 09 2002
PATEL & TRADEMARK OFFICE




FIG.3B

SEP 09 2002

Inventor(s): SRIVASTAVA AND CHANDAWARKAR

Title: "METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTION USING HEAT SHOCK PROTEINS"




FIG.4A

SEP 09 2002

USPTO & TRADEMARK OFFICE

SEP 12 2002

TECH CENTER 1600/2900




FIG.4B




FIG.5A




FIG.5B




FIG.6A




FIG.6B



SEP 12 2002
TECH CENTER 1600/2900




FIG.7A




FIG.7B